MedPath

randomized study of Gemicitabine alone or UFT adjuvant chemotherapy for stage IB-IIIA non small cell lung cancer after complete resectio

Phase 3
Conditions
stage IB-IIIA non small cell lung cancer after complete resection
Registration Number
JPRN-C000000116
Lead Sponsor
West Japan Oncology Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
600
Inclusion Criteria

Not provided

Exclusion Criteria

1.small cell lung cancer or low grade malignancy of lung cancer 2.incomplete resection 3.apparant interstitial pneumonitis at chest rentogenogram 4.inadequate conditon for chemotherapy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
overall survival
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath